Screening and diagnosis

Classification and risk stratification

Perioperative care

Quality improvement

Patient education

Nonpharmacologic interventions

Therapeutic procedures

Respiratory support

Follow-up and surveillance

Specific circumstances

Preventative measures

Medical management

Surgical interventions

Inpatient care

Diagnostic procedures

Diagnostic investigations

Insufficient evidence to make a recommendation.

Strongly favor this test or intervention.

The calculator in question is the World Health Organization (WHO) Criteria for Essential Thrombocythemia. Essential Thrombocythemia (ET) is a rare chronic blood disorder characterized by the overproduction of platelets by megakaryocytes in the bone marrow. 

The WHO criteria for ET is used in the diagnosis of this condition. It applies to patients who present with persistent thrombocytosis and are suspected of having a myeloproliferative disorder. 

The clinical utility of this calculator is to aid in the diagnosis of ET, which can help guide treatment decisions and patient management. It can also help differentiate ET from other myeloproliferative disorders, such as polycythemia vera or primary myelofibrosis.

The WHO criteria for ET includes both major and minor criteria, which encompass platelet counts, bone marrow characteristics, and the absence of criteria for other myeloproliferative disorders. 

Exclusion criteria for the use of this calculator would be the presence of conditions that could cause reactive thrombocytosis, such as iron deficiency, infection, or malignancy. Additionally, it should not be used in patients who meet the criteria for other myeloproliferative disorders.

WHO criteria for essential thrombocythemia

# Description:
The calculator in question is the World Health Organization (WHO) Criteria for Essential Thrombocythemia. Essential Thrombocythemia (ET) is a rare chronic blood disorder characterized by the overproduction of platelets by megakaryocytes in the bone marrow. 

The WHO criteria for ET is used in the diagnosis of this condition. It applies to patients who present with persistent thrombocytosis and are suspected of having a myeloproliferative disorder. 

The clinical utility of this calculator is to aid in the diagnosis of ET, which can help guide treatment decisions and patient management. It can also help differentiate ET from other myeloproliferative disorders, such as polycythemia vera or primary myelofibrosis.

The WHO criteria for ET includes both major and minor criteria, which encompass platelet counts, bone marrow characteristics, and the absence of criteria for other myeloproliferative disorders. 

Exclusion criteria for the use of this calculator would be the presence of conditions that could cause reactive thrombocytosis, such as iron deficiency, infection, or malignancy. Additionally, it should not be used in patients who meet the criteria for other myeloproliferative disorders.
---
# Inputs:
# Major criteria
A. Platelet count >= 450×10**9/L
B. Bone marrow biopsy showing proliferation mainly of the megakaryocyte lineage with increased numbers of enlarged, mature megakaryocytes with hyperlobulated nuclei. No significant increase or left shift in neutrophil granulopoiesis or erythropoiesis and very rarely minor (grade 1) increase in reticulin fibers
C. Not meeting World Health Organization criteria for BCR-ABL1+ CML, PV, PMF, myelodysplastic syndromes, or other myeloid neoplasms
D. Presence of JAK2, CALR, or MPL mutation 
# Minor criterion
E. Presence of a clonal marker or absence of evidence for reactive thrombocytosis
---
# Scoring:
- If (A and B and C and D) or (A and B and C and E), then Diagnostic criteria are met
- If true, then Diagnostic criteria are not met)

The Revised International Prognostic Score for Essential Thrombocythemia (IPSET-thrombosis) is a clinical calculator used in the management of patients with essential thrombocythemia (ET). Essential thrombocythemia is a rare chronic blood disorder characterized by the overproduction of platelets by megakaryocytes in the bone marrow. 

The Revised IPSET score is used to stratify patients into risk categories (low, intermediate, and high) based on their likelihood of developing thrombotic complications. This score takes into account factors such as age, prior thrombosis, cardiovascular risk factors, and JAK2 V617F mutation status. 

The clinical utility of this calculator is to guide clinicians in making treatment decisions, such as the initiation of cytoreductive therapy or low-dose aspirin, and to provide patients with a prognosis regarding their risk of thrombosis. 

There are no specific exclusion criteria for the use of the Revised IPSET score, but it should be noted that it is only applicable to patients with a confirmed diagnosis of essential thrombocythemia. It is not intended for use in patients with other myeloproliferative disorders or in those without a definitive diagnosis.

Revised IPSET score for essential thrombocythemia

# Description:
The Revised International Prognostic Score for Essential Thrombocythemia (IPSET-thrombosis) is a clinical calculator used in the management of patients with essential thrombocythemia (ET). Essential thrombocythemia is a rare chronic blood disorder characterized by the overproduction of platelets by megakaryocytes in the bone marrow. 

The Revised IPSET score is used to stratify patients into risk categories (low, intermediate, and high) based on their likelihood of developing thrombotic complications. This score takes into account factors such as age, prior thrombosis, cardiovascular risk factors, and JAK2 V617F mutation status. 

The clinical utility of this calculator is to guide clinicians in making treatment decisions, such as the initiation of cytoreductive therapy or low-dose aspirin, and to provide patients with a prognosis regarding their risk of thrombosis. 

There are no specific exclusion criteria for the use of the Revised IPSET score, but it should be noted that it is only applicable to patients with a confirmed diagnosis of essential thrombocythemia. It is not intended for use in patients with other myeloproliferative disorders or in those without a definitive diagnosis.
---
# Inputs:
A. Age > 60 years
B. JAK2V617F mutation
C. History of thrombosis
---
# Scoring:
- If (A and B) or C, then Risk of thrombosis is high
- If A, then Risk of thrombosis is intermediate
- If B, then Risk of thrombosis is low
- If true, then Risk of thrombosis is very low)

The IPSET (International Prognostic Score for Essential Thrombocythemia) score is a clinical calculator used specifically for patients diagnosed with essential thrombocythemia, a rare chronic blood disorder characterized by the overproduction of platelets by megakaryocytes in the bone marrow. 

The IPSET score is used to stratify patients into risk categories (low, intermediate, and high) based on their risk of thrombotic events, which are common complications of essential thrombocythemia. The score takes into account factors such as age, thrombosis history, cardiovascular risk factors, and JAK2 V617F mutation status. 

The clinical utility of the IPSET score lies in its ability to guide treatment decisions and monitor disease progression. It helps clinicians to determine the intensity of treatment required, with higher scores indicating a need for more aggressive treatment strategies. 

There are no specific exclusion criteria for the use of the IPSET score, but it should be noted that it is only applicable to patients with a confirmed diagnosis of essential thrombocythemia. It is not intended for use in patients with other types of thrombocytosis or blood disorders.

IPSET score for essential thrombocythemia

# Description:
The IPSET (International Prognostic Score for Essential Thrombocythemia) score is a clinical calculator used specifically for patients diagnosed with essential thrombocythemia, a rare chronic blood disorder characterized by the overproduction of platelets by megakaryocytes in the bone marrow. 

The IPSET score is used to stratify patients into risk categories (low, intermediate, and high) based on their risk of thrombotic events, which are common complications of essential thrombocythemia. The score takes into account factors such as age, thrombosis history, cardiovascular risk factors, and JAK2 V617F mutation status. 

The clinical utility of the IPSET score lies in its ability to guide treatment decisions and monitor disease progression. It helps clinicians to determine the intensity of treatment required, with higher scores indicating a need for more aggressive treatment strategies. 

There are no specific exclusion criteria for the use of the IPSET score, but it should be noted that it is only applicable to patients with a confirmed diagnosis of essential thrombocythemia. It is not intended for use in patients with other types of thrombocytosis or blood disorders.
---
# Inputs:
A. Age > 60 years (+1)
B. Cardiovascular risk factors (such as hypertension, diabetes mellitus, or current smoking) (+1)
C. JAK2V617F mutation (+2)
D. History of thrombosis (+2)
---
# Scoring:
- If score >= 3, then Risk of thrombosis is high
- If score == 2, then Risk of thrombosis is intermediate
- If score <= 1, then Risk of thrombosis is low
- If score == 0, then Please make a selection)

Essential thrombocythemia

Guidelines

Key sources